Date: 2013-08-27
Type of information: Treatment of the first patient
phase: 1-2a
Announcement: treatment of the first patient
Company: Virttu Biologics (UK)
Product: Seprehvir® (HSV1716)
Action
mechanism: oncolytic virus/oncolytic immunotherapy. Seprehvir® is an engineered oncolytic herpes simplex virus designed to selectively target and destroy cancerous cells whilst leaving healthy cells unharmed.
Disease: malignant pleural mesothelioma
Therapeutic area: Cancer - Oncology
Country: UK
Trial
details: This phase 1/2 study is in 2 parts. Part A will recruit 3 people. Part B will recruit up to 9 people. Everyone will have HSV1716. People in part 1 have 1 dose of HSV1716. If they don’t have serious side effects then the study will go on to part B. The first 3 people in part B will have 2 doses of HSV1716. If they don’t have serious side effects the next 6 will have 4 doses. (NCT01721018)
Latest
news: * On August 27, 2013, Virttu Biologics, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced that it has treated the first cohort of patients in its Phase I/IIa clinical study of its oncolytic virus, Seprehvir® (HSV1716) for the treatment of malignant pleural mesothelioma.The study is being conducted at the Weston Park Hospital (Sheffield Teaching Hospitals NHS Foundation Trust) under the clinical leadership of Professor Penella Woll. The primary objective of the study is to determine the safety and tolerability of Seprehvir® when given both as single and repeat intrapleural doses in patients with inoperable, malignant pleural mesothelioma; a form of lung cancer that is almost exclusively caused by occupational exposure to certain types of asbestos.The first cohort of patients was treated with a single dose of Seprehvir®. The treatment was well tolerated with no dose limiting toxicity or serious adverse events related to treatment. The current safety profile supports continued recruitment of patients into the second cohort, where patients will receive two doses, one week apart.
